|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
CONCURRENT USE MAY SOMETIMES CAUSE SEVERE AND FATAL SIDE EFFECTS
|
THYROID DRUGS MAY HAVE DECREASED PLASMA LEVELS DUE TO INCREASED METABOLISM BY THE DRUG
|
THYROID DRUGS MAY HAVE DECREASED PLASMA LEVELS DUE TO INCREASED METABOLISM BY THE DRUG
|
THYROID DRUGS MAY HAVE DECREASED PLASMA LEVELS DUE TO INCREASED METABOLISM BY THE DRUG
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
DIGOXIN CONCENTRATION IS INCREASED
|
DIGOXIN CONCENTRATION IS INCREASED
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
SEROTONIN SYNDROME MAY OCCUR DUE TO INCREASED PLASMA LEVELS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
|
SEROTONIN SYNDROME MAY OCCUR DUE TO INCREASED PLASMA LEVELS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
|
SEROTONIN SYNDROME MAY OCCUR DUE TO INCREASED PLASMA LEVELS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
|
SEROTONIN SYNDROME MAY OCCUR DUE TO INCREASED PLASMA LEVELS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
|
SEROTONIN SYNDROME MAY OCCUR DUE TO INCREASED PLASMA LEVELS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
|
SELECTIVE SEROTONIN INHIBITORS MAY VERTUALLY ABOLISH THE METABOLISM OF THE DRUG TO ITS ACTIVE METABOLITE BY INHIBITION OF HEPATIC ENZYMES
|
CO-ADMINISTRATION CAN INCREASE PLASMA LEVELS OF CICLESONIDE LEADING TO INCREASED CHANCES OF CUSHING SYNDROME
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
PHENYTOIN SERUM LEVELS ARE INCREASED BY THE DRUG
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS MAY ANTAGONISE THE ACTIVITY OF ANTIEPILEPTICS BY LOWERING THE CONVULSIVE THRESHOLD, SO INCREASE THE DOSE OF ANTIEPILEPTICS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
DILTIAZEM UNDERGOES BIOTRANSFORMATION BY CYTOCHROME P450 MIXED FUNCTION OXIDASE ; CO-ADMINISTRATION MAY RESULT IN INCREASED SERUM CONCENTRATION OF DILTIAZEM, PROBABLY DUE TO INHIBITED OXIDATIVE METABOLISM OF DILTIAZEM BY FLUVOXAMINE
|
CONCURRENT USE MAY CAUSE DELIRIUM
|
SELECTIVE SEROTONIN INHIBITORS MAY INHIBIT ITS ELIMINATION LEADING TO INCREASED BLOOD LEVELS
|